Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

NCT00488592 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

NIH

Sponsor class

Conditions

Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia (CML)

Interventions

BIOLOGICAL: WT1:126-134
BIOLOGICAL: PR1:169-177 Peptide
DRUG: GM-CSF (Sargramostim)
BIOLOGICAL: Montanide adjuvant

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)